DeesE.C., O'Reilly, GoodmanS.N.: A prospective pharmacologic evaluation of age-related toxicityof adjuvant chemotherapy in women with breast cancer. Cancer Invest, 18: 521–529, 2000
2.
IbrahimN.K., FryedK, BuzdarA.U.: Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Arch Intern Med, 156: 882–886; 1996.
3.
CupplesL.A., D'AgostinoR.B.: Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennal measurements: Framingham heart study, 30-yeras follow-up. In: KannelWB, WolfPA, GarrisonRT (eds), the Framingham study: an epidemiological investigation of cardiovascular diseases. (NIH no. 87-2703) National Heart, Lung and Blood Institute, 1987.
4.
Von HoffD.D., LayardM.W., BasaP.: Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med91: 710–717, 1979.
5.
VenturiniM., MichelottiA., Del MastroL.: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol14: 3112–3120, 1996.
6.
IbrahimN.K., HortobagyiG.N., EwerM.: Doxorubicin-in-duced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol, 43: 471–478, 1999.
7.
Van der MaaseH., HansenS.W., RobertsJ.T.: Gemcitabine and Cisplatin versus methotrexate, vinblastine, doxorubicin, and cislatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 17: 3068–3077, 2000.
8.
SonneveldP., De RidderM., Van der LelieH.: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol, 13: 2530–2539, 1995.
9.
TirelliU., ErranteD., Van GlabbekeM.: CHOP is the standard regimen in patients > 70 years of age with intermediate-grade and high-grade non-Hodgkin lymphoma: results of a randomized study of the european Organization for Research and Treatment of Cancer lymphoma cooperative study group. J Clin Oncol, 16: 27–34, 1998.
10.
MainwaringP.N., CunninghamD., GregoryW.: Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood, 97: 2991–2997, 2001.
